EGFR and non-small cell lung carcinoma: Recently, a whole-body PBPK model was established for the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) osimertinib to capture heterogeneous tissue distribution and target engagement in NSCLC.